FDAnews Drug Daily Bulletin

NEXMED REPORTS 2005 FINANCIAL RESULTS

March 20, 2006
A A

NexMed, Inc., a developer of innovative pharmaceutical products based on its proprietary NexACT transdermal drug delivery technology, today announced 2005 financial results. For the year ended December 31, 2005, the Company recorded revenue of $2,399,161 compared to $359,369 for the same period in 2004. The 2005 revenue is primarily attributable to the revenue recognized in connection with our Novartis licensing agreement.

MarketWire (http://www.marketwire.com/mw/release_html_b1?release_id=113588)